MAMs form a crucial platform for interorganelle molecule exchange and cross-talk, governing calcium homeostasis, lipid metabolism, and apoptosis regulation
This portfolio reflects Lillys strategy of pursuing multiple complementary approaches to metabolic disease: Tirzepatide : Dual GIP/GLP-1 agonist (approved, injectable) Retatrutide : Triple GIP/GLP-1/glucagon agonist (Phase 3, injectable) Orforglipron : Oral GLP-1R agonist (Phase 3, oral) If retatrutide is approved, it could be positioned as a more potent option for patients requiring greater weight loss or those with MASLD, while tirzepatide and orforglipron serve other patient segments
Epithelial crosstalk at the microbiotamucosal interface
Early diagnosis and quick treatment with L-carnitine have significantly improved chances of recovery
Knop: Back in 2009, in my effort to better understand how the gut hormone glucagon-like peptide 1 (GLP-1) is secreted, I read TGR5-mediated bile acid sensing controls glucose homeostasis (Thomas, et al.), which described how bile acids may stimulate the secretion of this glucose-lowering and satiety-promoting hormone
People with existing hormonal issues or those undergoing Hormone Therapy should be especially cautious